Takeda Pharmaceutical Company Limited (TAK) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en Tokyo, Japan. El CEO actual es Christophe Weber.
TAK tiene fecha de IPO 2010-01-05, 49,281 empleados a tiempo completo, cotiza en el NYSE, una capitalización de mercado de $56.39B.
Takeda Pharmaceutical Company Limited is a globally diversified pharmaceutical company headquartered in Tokyo, Japan, with operations across North America, Europe, Latin America, Russia, and Asia. Founded in 1781, Takeda engages in the research, development, manufacturing, and commercialization of pharmaceutical products across key therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company markets numerous branded products such as Entyvio, Velcade, Adcetris, and Trintellix, and maintains an extensive portfolio of strategic collaborations and licensing agreements with leading biotech firms and research institutions to support its pipeline development and innovation initiatives.
